Q3 earnings miss weighs on Monopar Therapeutics stock price as downward momentum persists

Traders Union
All News
Stocks
Monopar Therapeutics drops 4.4% to $69.23

Highlights

Monopar Therapeutics reported a third-quarter 2026 net loss of $6.2 million, or $0.72 per share, with the loss widening year over year but earnings per share beating consensus by $0.10.
Monopar Therapeutics held $129.4 million in cash as of September 30, 2026, supporting ongoing clinical and regulatory activity including a rolling NDA submission for ALXN1840 in Wilson disease.
Shares of Monopar Therapeutics trade below key moving averages on multiple timeframes with mixed momentum readings; price is expected to consolidate in the $65.63 to $77.80 range over the next 2 to 3 days, with a 63% probability of an upward move.

Earnings beat and strong cash buffer offset widened quarterly loss

Monopar Therapeutics reported a third-quarter 2026 net loss of $6.2 million, or $0.72 per share, which was wider than the loss a year earlier, as operating expenses increased to support clinical and regulatory activities, according to Panabee. Despite the higher loss, the company outperformed consensus expectations with an earnings per share result that beat forecasts by $0.10, according to MarketBeat. Monopar Therapeutics also maintained a solid cash position of $129.4 million as of September 30, 2026, supporting operational stability in the near term, as reported by Globenewswire. The company's rolling NDA submission for ALXN1840 in Wilson disease was on track for completion within weeks of the third quarter of 2026, according to Panabee, though price action has remained under broader selling pressure.

Mixed momentum readings with overbought signals cap upside near resistance

On the technical side, MNPR is trading below the MA-20 and MA-50 on the hourly chart, as well as below the MA-200 on the daily timeframe. The Ichimoku Kijun sits at $71.35 and acts as immediate resistance. Momentum signals are mixed, with both MACD and the Awesome Oscillator showing neutral readings, while ADX points to a buy bias. The RSI and Stoch RSI are neutral, and the CCI is overbought, suggesting some caution for bulls. Bull/Bear Power is positive at 2.47, indicating intraday dominance by buyers even as the daily price fell with moderate volatility.

Sideways trading outlook as odds favor rebound above resistance

For the next 2–3 trading days, the price is expected to remain within a volatility band between $65.63 and $77.80. The baseline scenario sees MNPR consolidating sideways within this range. The likelihood of an upward move is moderately higher, with a 63% probability assigned to an advance above immediate resistance, while the chance of a further decline below support is 37%. A firm break above the Ichimoku Kijun at $71.35 would be required for a sustained bullish run, whereas a close below $65.63 could signal renewed selling momentum.

Anton Kharitonov, expert at Traders Union, sees Monopar Therapeutics in a defensive position after a wider third-quarter loss and continued downside momentum. Despite a positive earnings surprise and a strong cash runway, technical readings indicate mixed momentum and resistance near $71.35, with the stock still pressured below all key moving averages. The company’s clinical progress has yet to improve short-term sentiment, and the trading range remains capped unless key resistance breaks decisively. "Until MNPR reclaims the Ichimoku Kijun and finds sustained buying, I remain cautious and will wait for a clear signal before considering upside scenarios."

Earlier, analysts noted that Monopar Therapeutics was experiencing technical consolidation with buyers showing intraday dominance, but momentum signals remained mixed. The current analysis adds further nuance by highlighting a shift toward increased downside pressure, making a decisive move above the $71.35 Ichimoku Kijun level an important trigger to monitor for any potential bullish reversal.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.